Risk of Lymphoma Associated With Combination Anti–Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis  Corey A. Siegel, Sadie M. Marden, Sarah M. Persing, Robin J. Larson, Bruce E. Sands  Clinical Gastroenterology and Hepatology  Volume 7, Issue 8, Pages 874-881 (August 2009) DOI: 10.1016/j.cgh.2009.01.004 Copyright © 2009 AGA Institute Terms and Conditions

Figure 1 Flow diagram of the studies identified in search, and reasons for study exclusion. Clinical Gastroenterology and Hepatology 2009 7, 874-881DOI: (10.1016/j.cgh.2009.01.004) Copyright © 2009 AGA Institute Terms and Conditions

Figure 2 Heterogeneity among the studies. The relative risk of NHL (compared with SEER) is plotted against the absolute rate per 10,000 patient-years for each study. Twenty of the 26 studies did not have any reported cases of lymphoma. The outlier study with the highest rate is Ljung et al.16 Clinical Gastroenterology and Hepatology 2009 7, 874-881DOI: (10.1016/j.cgh.2009.01.004) Copyright © 2009 AGA Institute Terms and Conditions